Appendix B. Additional trial characteristics.
| Study | Supplement Duration (Years) |
Baseline Age |
Sex (%M) |
Form** | Appropriate Randomization Scheme |
Appropriate Blinding Method |
Sufficient Follow-up |
|---|---|---|---|---|---|---|---|
| Avenell et al., 2005[41] | 1 | 72 | 96 | 0 | Y | Y | Y |
| Girodon et al., 1997[42] | 2 | 84 | 25 | 9 | Y | N | Y |
| Girodon et al., 1999[43] | 2 | 83 | 25 | 9 | Y | Y | Y |
| CTNSARC, 2009[44] | 9 | 68 | 55 | 9 | Y | Y | Y |
| Blot et al., 1993[45] | 5.25 | 55 | 50 | 0 | N | N | Y |
| Hercberg et al., 2004[46] | 7.54 | 49 | 39 | 0 | Y | Y | Y |
| Chandra et al., 1992[47] | 1 | 74 | 73 | 9 | Y | Y | Y |
| Pike and Chandra, 1995[48] | 1 | 69 | 28 | 0 | Y | Y | Y |
| Wright et al., 2006[49] | 6.1 | 58 | 100 | 0 | Y | Y | Y |
| Li et al., 1993[50] | 6 | 54 | 44 | 0 | Y | N | Y |
| Takamatsu et al., 1995[51] | 6 | 47 | 37 | 1 | N | Y | Y |
| Meydani et al., 2004[52] | 1 | 85 | 34 | 0 | Y | Y | Y |
| ARMDS, 1996[53]* | 1.5 | 72 | 93 | 9 | N | Y | Y |
| You et al., 2001[54] | 3.25 | 47 | 51 | 9 | N | Y | Y |
| Graat et al., 2002[55] | 1 | 73 | 50 | 1 | Y | Y | Y |
| Salonen et al., 2003[56] | 6 | 60 | 49 | 1 | N | Y | Y |
| Cook et al., 2007[57] | 9.4 | 61 | 0 | 1 | N | Y | Y |
| Lee et al., 2005[8] | 10.1 | 55 | 0 | 1 | Y | Y | Y |
| GISSI, 1999[58]* | 3.5 | 59 | 85 | 0 | Y | N | Y |
| PPP, 2001[59]* | 3.6 | 64 | 58 | 0 | Y | N | Y |
| Bukin et al., 1997[60] | 1 | 55 | 39 | 1 | N | N | Y |
| Mooney et al., 2005[61] | 1.25 | 37 | 55 | 0 | N | N | Y |
| Milman et al., 2008[62] | 1.5 | 69 | 48 | 1 | Y | Y | Y |
| de Waart et al., 2001[63] | 1.8 | 60 | 100 | 0 | N | N | Y |
| McKeown-Eyssen et al., 1988[64] | 2 | 58 | 66 | 0 | N | Y | Y |
| Bairati et al., 2006[65] | 3 | 63 | 79 | 0 | Y | N | Y |
| Hodis et al., 2002[66] | 3 | 56 | 45 | 0 | Y | N | Y |
| Lonn et al., 2005[67] | 4.5 | 66 | 74 | 1 | Y | Y | Y |
| Lippman et al., 2008[9] | 5.46 | 62 | 100 | 0 | Y | Y | Y |
| AREDS, 2001[68]* | 6.3 | 68 | 45 | 0 | Y | Y | Y |
| Sesso et al., 2008[69] | 8 | 64 | 100 | 0 | Y | Y | Y |
| Greenberg et al., 1994[70] | 4 | 61 | 79 | 0 | Y | Y | Y |
| Antoniadi et al., 2008[71] | 1 | 60 | 40 | 9 | Y | N | N |
| de la Maza et al., 1995[72] | 1 | 49 | 85 | 9 | N | Y | Y |
| Richer et al., 2004[73] | 1 | 75 | 97 | 1 | Y | Y | Y |
| Wluka et al., 2002[74] | 2 | 64 | 42 | 1 | N | N | Y |
| Magliano et al., 2006[75] | 4 | 64 | 45 | 1 | Y | Y | Y |
| McNeil et al., 2004[76] | 4 | 66 | 44 | 1 | Y | Y | Y |
| Pathak et al., 2005[78] | 2 | 58 | 83 | 0 | Y | N | Y |
| Stephens et al., 1996[79] | 1.4 | 62 | 84 | 1 | Y | Y | Y |
| Plummer et al., 2007[80] | 3 | NA | 33 | 0 | Y | Y | Y |
| Takagi et al., 2003[81] | 5 | 63 | 40 | 9 | N | N | Y |
| CLIPS, 2006[82]* | 2 | 66 | 77 | 0 | Y | Y | Y |
| Chylack et al., 2002[7] | 3 | 68 | 41 | 0 | Y | Y | Y |
| MRC/BHF HPS, 2002[83]* | 5 | 40–80¶ | 70 | 0 | Y | Y | Y |
| Bugianesi et al., 2005[84] | 1 | 42 | 83 | 9 | Y | N | Y |
| Fang et al., 2002[85] | 1 | 51 | 88 | 9 | Y | Y | Y |
| Boaz et al., 2000[5] | 1.42 | 64 | 69 | 1 | Y | Y | N |
| Brown et al., 2001[86] | 3 | 53 | 87 | 1 | N | Y | Y |
| Waters et al., 2002[87] | 3 | 65 | 0 | 0 | Y | Y | Y |
| Desnuelle et al., 2001[77] | 1 | 64 | 55 | 9 | Y | Y | Y |
| Stevic et al., 2001[88] | 1 | 57 | 75 | 9 | -- | -- | -- |
| Singh et al., 2007[89] | 2 | 59 | 74 | 1 | N | N | Y |
| Sano et al., 1997[90] | 2 | 73 | 35 | 0 | Y | N | Y |
| Marras et al., 2005[91] | 2.6 | 61 | 66 | 0 | N | N | Y |
| Petersen et al., 2005[92] | 3 | 73 | 54 | 9 | Y | N | Y |
| Graf et al., 2005[93] | 1.5 | 58 | 65 | 0 | N | N | Y |
||
Dose is average of all doses assigned to parallel arms.
¶
Range; mean not reported. [16].
**
Form: 1 = Natural; 0 = Synthetic; 9 = Unknown